Gene therapeutics is a promising approach for diseases without effective conventional treatments, and maybe a useful alternative for expensive recombinant protein replacement therapies. Salivary glands (SGs) have several unique advantages as a target tissue for gene delivery, 1 and preclinical studies in the past decade have demonstrated their potential, in particular as a systemic gene therapeutics platform. 2 A key issue for all gene transfer applications is adequate control of transgene expression. High and uncontrolled levels of transgene expression, such as obtained with many commonly used constitutive promoters, are unnecessary and may be harmful. Therefore, it is desirable to use regulatory systems to control transgene expression that can be induced as needed and to the extent required.
Several systems are currently available for transgene regulation. These systems typically utilize a small molecule to activate a chimeric transcription factor. The rapamycin-inducible system employs the immunosuppresive drug rapamycin or nonimmunosuppresive analogues 3 and has been extensively tested following intramuscular gene transfer both in mice 4, 5 and nonhuman primates. 6 We have recently shown that the rapamycin-inducible system can be useful for regulating transgene expression in SGs. 7 In those studies, we employed a two-vector system, with first-generation serotype 5 adenoviral (rAd5) vectors. After administration of the rAd5 vector, robust and completely reversible, transgene expression was observed in rats. 7 However, such rAd5 vectors are unsuitable for achieving long-term transgene expression since they elicit a potent immune response. 8, 9 In the absence of immunosuppressive therapy, transgene expression from first generation rAd5 vectors in SGs is typically lost within 7-14 days.
Conversely, serotype 2 adenoassociated viral (AAV2) vectors mediate stable transgene expression in several tissues, including liver, 10 muscle, 11 eye, 12 as well as SGs. 2 Indeed, after SG gene transfer, rAAV2 vectors confer functional transgene expression, 13, 14 with only a modest immune response, 15 and mediate long-term, transgene expression in mice. 2 A recent report demonstrated the successful use of the rapamycin-inducible system in a non-human primate using a single AAV2 vector. 6 In this third-generation vector system, the chimeric transcription factor and transgene cassettes are assembled in a head-to-tail manner, still retaining the potency and efficacy of the original twovector system. 6 The purpose of the present study was to evaluate the potential of this single AAV2 rapamycininducible transcriptional regulation system in SGs using human erythropoietin (hEPO) as a reporter gene.
For preliminary dose-response experiments, we delivered 10 8 , 10 9 or 10 10 vector (rAAV-TF2.3-hEPO) particles/mouse by retroductal infusion. Following administration of rapamycin (3 mg/kg; a dose previously shown useful in rats), 7 and measurement of serum hEPO levels, the optimal vector dose determined was 10 10 particles/mouse administered to a single submandibular gland. All subsequent experiments herein presented were conducted with this vector dose. Importantly, in the absence of rapamycin administration, no hEPO was detected in mouse serum (see below).
We next examined the decay kinetics of serum hEPO levels elevated in response to a single dose of rapamycin (3 mg/kg; Figure 1 ). At 1 day after administration of rapamycin to animals transduced 4 weeks earlier with 10 10 particles of rAAV-TF2.3-hEPO, serum levels of hEPO were significantly elevated; in this set of experiments to 59.6751.5 mU/ml (mean7s.d.). From this peak level, serum hEPO was decreased by B50% on day 3, and thereafter further declined, returning to background levels by day 14 after rapamycin administration. These serum hEPO decay kinetics are similar to those reported following rapamycin induction in both transduced murine muscle 5 and eye. 12 Previously, we have reported that transgene expression in SGs mediated by unregulated AAV2 vectors led to stable hEPO expression after 8-12 weeks. 2 Similarly, relatively stable serum hEPO levels were attained 8-12 weeks after delivery of rAAV-TF2.3-hEPO (Figures 2 and  3 ). This pattern allows determination of the rapamycin dose-dependence of serum hEPO after B2 months. Accordingly, we examined the rapamycin dose-dependence of serum hEPO levels in a second cohort of mice between weeks 9 and 20 after SG administration of 10 10 particles of rAAV-TF2.3-hEPO ( Figure 2a) . As previously noted, no hEPO was detected in serum without rapamycin. Rapamycin doses of 0.3, 1 and 3 mg/kg yielded an induced serum hEPO level (mean7s.d.) of 59.8727, 237.27106, and 333.47178 mU/ml, respectively (with a 14-day-interval between different rapamycin doses). Figure 2b shows representative results obtained from a single mouse followed for 25 weeks postvector delivery. In this animal, serum hEPO levels were considerably elevated in response to rapamycin (3 mg/kg) between weeks 7 and 11. Thereafter, hEPO levels were dose- 2,7 The vector was dialyzed against 1 l saline at 41C overnight before viral delivery. Vector was diluted to the required dose with saline, kept on wet ice until infusion, and then administered in a 50 ml volume. Rapamycin was initially dissolved in N, N-dimethylacetamide at a concentration of 5 mg/ml and stored at À201C. 7 Shortly before use, an equal volume of rapamycin (freshly diluted to 3 mg/ml) was mixed with PEG400: Tween 80 (9:1) and vortexed until homogenized, resulting in a 1.5 mg/ml final concentration. Rapamycin was diluted as needed in the same solution, and administered on day zero at 2 ml/g body weight by intraperitoneal injection. Blood was obtained from the retro-obital plexus and serum hEPO was determined by a specific enzyme-linked immunosorbent assay (ELISA; StemCell Technology Inc., Vancouver, BC, Canada) according to the manufacturer's instructions. Values presented are mean7s.d. of four mice. The plasmid pAAV-TF2.3-hEPO was the same as reported previously, 6 except that rhesus EPO cDNA was replaced by hEPO cDNA (obtained from pEAK8; a generous gift of Dr Y Terada). Restriction endonuclease digestions with SmaI and BssHII, as well as sequencing, were used to show correct construction of the vector and the presence of intact ITRs. The AAV2 vector rAAV-TF2.3-hEPO was generated by cotransfection of pAAV-TF2.3-hEPO with pDG, which provides the Rap and Cap proteins in trans (a generous gift of Prof J Kleinschmidt), into NAUT cells (Microbix Biosystems Inc, Toronto, Canada). Vector was purified by CsCl gradient centrifugation, as previously reported. 2 Rapamycin-induced transgene expression, for both the plasmid and AAV2 vector, was confirmed in vitro in 293 cells. Rapamycin (1 mM) was added to the medium and cells were incubated overnight prior to assaying media with the above ELISA kit. Vector titers were determined by real-time quantitative-PCR using transgene-specific primers. Blood was obtained 24 h post-rapamycin administration and serum hEPO (indicated by bars) was determined by ELISA, as described in Figure 1 . Hematocrit values (indicated by a discontinuous line) were determined by the microcapillary method, as previously reported.
2 (a) Rapamycin dose-dependence of hEPO expression in serum. Mice in this cohort were followed for up to 20 weeks posttransduction. All serum hEPO levels were measured 24 h postrapamycin administration. hEPO levels shown in the absence of rapamycin were obtained at week 9, while the hEPO levels for rapamycin doses 0. Regulated hEPO expression from salivary glands J Wang et al dependent and were associated with subsequent elevations in hematocrit levels. In particular, note that the two single doses of 3 mg/kg rapamycin administered at weeks 21 and 25, resulted in almost identically induced serum hEPO levels, 131.0 and 128.7 mU/ml, respectively. For the time period studied, these results suggest reliable and regulated transgene expression is occurring. From a therapeutic perspective, it is important to be able to maintain stable, nonfluctuating hEPO and hematocrit levels over an extended time period. Based on the above-described kinetic and dosing experiments, we hypothesized weekly dosing with rapamycin (3 mg/ kg) postadministration of rAAV-TF2.3-hEPO would lead to a gradual increase in serum hEPO and hematocrit levels, likely reaching a plateau after 8-12 weeks. As shown in Figure 3 , a third cohort of mice was administered rapamycin (3 mg/kg) each week starting at week 4 after viral delivery. Induced serum hEPO levels gradually increased and reached a plateau at approximately week 10. At this time-point, the average induced serum hEPO level (mean7s.d.) was 68.1761.9 mU/ml, while at weeks 11 and 12 the serum hEPO levels were 47.2748.1 and 63.1750.1 mU/ml, respectively. These data indicate that weekly rapamycin dosing in Balb/c mice is sufficient to maintain relatively stable serum hEPO levels. Subsequently, we tested hEPO production after longer intervals between rapamycin administration, allowing serum hEPO levels to completely return to, and be maintained at, zero prior to rapamycin readministration. As depicted in Figure 3 , monthly rapamycin administration induced serum hEPO to the same levels: at week 16, the average induced serum hEPO level achieved was 72.4732.3 mU/ml, at week 21, 82.27 28.2 mU/ml, and at week 25, 81.2710.3 mU/ml. Hematocrit levels were similarly elevated (Figure 3) .
The stable induction of hEPO levels for 6 months also suggests there was no appreciable immune response to the transcription factors, the transgene product or the vector over the course of this study. It is highly unlikely that a lack of immune response to the regulation system or transgene can be attributed to the immunosuppressive effects of rapamycin. In humans, daily administration of rapamycin is useful to prevent transplant rejection, but immunosuppressive activity is dramatically diminished when the drug is administered weekly. 16 In our studies, rapamycin was administered only infrequently, at intervals from 1 to 5 weeks. The apparent lack of an immune response to the components of the regulatory system are likely in part a reflection of the AAV delivery system and the target tissue, as evidenced by our earlier reports of stable expression of foreign gene products using AAV2 vectors. 2, [13] [14] [15] While the regulatory constructs used are almost entirely humanized (apart from a single point mutation in the FRB domain, and sequences at the junctions of different functional domains), there are still additional differences between these human sequences and the corresponding mouse genes, which we left unchanged. Finally, we have shown previously that at this level of transgene expression Balb/c mice do not develop an antibody response to human Epo. 2 Peak serum hEPO levels induced by rapamycin with this single, regulated AAV2 vector were robust, and similar to those achieved with a conventional AAV2 vector using a strong constitutive promoter (i.e., RSV 2 ), albeit at a 10-fold higher vector dose. However, unlike the results obtained following intramuscular delivery of a dual vector system in rhesus monkeys, 6 in SGs we did not observe an initial hyper-responsive phase (i.e., higher expression levels of hEPO in response to rapamycin early after transduction compared with that seen at later times). Rather, despite using relatively high levels of rapamycin as early as 2 weeks post-transduction, we consistently observed a gradual increase in transgene expression over the initial 8-12 week period. Thereafter, relatively stable induction of hEPO expression was evident. This pattern is consistent with the transgene expression in SGs after conventional AAV2 vector transduction. 2 This gradual rise of transgenic protein expression over time may be due to a relatively slow kinetic efficiency, compared to that in other tissues such as airway epithelia, liver, and muscle, of one or more of the multiple steps in the AAV2 transduction pathway. [17] [18] [19] [20] [21] These steps include uncoating of vector genomes in the nucleus and capsid processing by proteasomes, second strand synthesis of the AAV2 genome, and genome concatamerization. [17] [18] [19] [20] [21] Additional studies are needed to fully understand the mechanisms underlying AAV2 vector transduction in SGs.
After this initial 8-12 week period, rapamycin administration, over a 10-fold concentration range (0.3-3.0 mg/ kg), was able to consistently regulate the extent of hEPO expression and, consequently, hematocrit levels. Furthermore, peak hEPO levels were reduced B50% within 3 days. Thus, weekly rapamycin dosing was sufficient for adequate and sustained functional responses in these Balb/c mice. Hematocrits were maintained in a high, but stable, range (B60-70%), which importantly could be 2 Serum hEPO levels following weekly rapamycin administration in this cohort of mice (n ¼ 3 until week 12; one animal died thereafter, apparently as a result of intestinal adhesions at the intraperitoneal rapamycin injection site) were relatively stable after week 10, as previously observed with conventional promoters. 2 Administration of a single monthly dose of rapamycin (3 mg/kg; at weeks 16, 21 and 25) repeatedly resulted in similar peak serum hEPO levels up until the end of the experiment (week 25). During these latter larger time intervals, serum hEPO levels were always undetectable a week prior to rapamycin administration (i.e., weeks 15, 20 and 24) . Data shown are mean7s.d.
Regulated hEPO expression from salivary glands J Wang et al reduced by ceasing to administer rapamycin and thus preventing hEPO expression. Such control is necessary with hEPO, since unregulated expression could result in a serious adverse effect, polycythemia. For other transgene products, for example, growth hormone, other kinetic patterns are expected to be required.
In the present study, three separate cohorts of mice were used, all demonstrating similar responses. Thus, our data, demonstrate that use of the rapamycininducible gene expression system in a single rAAV2 vector permits reproducible, long-term and relatively tight regulation of a functional transgene following SG gene transfer in mice. These results are similar to those recently reported after intramuscular delivery of a similarly constructed single AAV2 vector (but encoding rhesus EPO) to a rhesus monkey. 6 In that study, regulated rhesus EPO production was observed for 420 months (length of study) and was completely dependent on dimerizer drug delivery. 6 The single AAV2 vector described herein seems to retain the desirable features of the earlier generation rapamycin regulation systems, employing two vectors, as previously reported in muscle 5, 6 and eye, 12 as well as SG, 7 and therefore seems to be a practical gene delivery tool for long-term therapeutics.
In summary, we have demonstrated in vivo that longterm and reliable rapamycin dose-dependent regulation of a therapeutic transgene (hEPO) does occur after SG delivery of a single AAV2 vector. Our results support the concept that SGs can potentially serve as a gene transfer target site for the long-term, regulated production of therapeutic proteins useful for the management of systemic single protein deficiency disorders. 22 Using transgenes as drugs offers the potential for more favorable pharmacokinetics than provided with recombinant therapeutic proteins, typically administered in repetitive, bolus parenteral injections. 23, 24 
